Warning: in_array() expects parameter 2 to be array, null given in /home/pharmalicensing/public_html/detail.php on line 234

Warning: in_array() expects parameter 2 to be array, null given in /home/pharmalicensing/public_html/inc_stats.php on line 82

Warning: array_push() expects parameter 1 to be array, null given in /home/pharmalicensing/public_html/inc_stats.php on line 85
Pharmalicensing | Life Science's Global Technology Marketplace
Save this technology
close
Save to Existing Project
Save to a New Project
EGT022 (human Derived Recombinant Polypeptide)
Korea Health Industry Development Institute (KHIDI) South Korea flag South Korea
Abstract ID:
EG-Decorin accelerates wound healing through a reduction of edema, maturation and stabilization of impaired vessels, and enhanced replacement of granulation tissues on ischemic wounds. EGT022 may have potential benefits for other ischemic disorders such a...
Contact Heajin Jung
Participants
You
Email me a copy of this message

- EG-Decorin (compound name: EGT022), a topical ointment for pressure sore and diabetic foot ulcer, induces rapid repair of damaged capillaries. Thus, it promotes enhanced wound healing. EG-Decorin is majorly composed of human-derived protein ADAM-15 and repairs capillaries via recruiting pericytes.

- In the molecular aspect, EGT022 is a RGD motif containing recombinant polypeptide from human derived protein ADAM-15. EGT022 has a molecular weight of 6.1- kDa and is composed of over 58 amino acids.

- EGT022 is a therapeutic agent for chronic ischemic disorders such as pressure sore, diabetic foot ulcer.

- EG-Decorin (EGT022) is first in class with the new RGD motif mechanism.
- EG-Decorin accelerates wound healing through a reduction of edema, maturation and stabilization of impaired vessels, and enhanced replacement of granulation tissues on ischemic wounds.
- No significant toxicity was observed in pre-clinical toxicology studies.
- EGT022 may have potential benefits for other ischemic disorders such as diabetic retinopathy.

- EG-Decorin induces accelerated wound closure and replacement of granulation tissue in pressure sore induced in normal, diabetic, steroid treated, and old aged mice models.
- EG-Decorin improves proliferative activities of epidermal cells in rabbit full-thickness ear wound model.
- EG-Decorin does not induce skin contraction on the wound lesion during wound healing.
- EG-Decorin improves micro-vascular disorders caused by ischemia-reperfusion cycles.
- EG-Decorin promotes stabilization and maturation of impaired vessels in wounded lesions.
- Expression system in Pichia pastoris and 250L production and purification process has been established.

GO PREMIUM TO GET PATENT INFORMATION
Type of Business Relationship Sought
- Out licensing
- Collaboration
FEATURED
Last Updated Jun 2016
Technology Type THERAPEUTIC
Phase of Development CLINICAL TRIALS
GOVERNMENT INSTITUTE